 |
Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes |
|---|---|
| Trade Name | |
| Orphan Indication | Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations |
| USA Market Approval | USA |
| USA Designation Date | 2005-06-03 00:00:00 |
| Sponsor | Astellas Pharma Global Development, Inc.;1 Astellas Way;Northbrook, Illinois, 60062 |
